Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix
Neuroendocrine carcinoma of the cervix (NECC) is a highly aggressive and rare gynecological malignancy with a poor prognosis. Despite aggressive local and systemic treatments, there are high rates of locoregional recurrence and distant metastases. Therefore, more potent treatments are required to ma...
Main Authors: | Rongyu Liu, Xinlin He, Zhengyu Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1029598/full |
Similar Items
-
Efficacy of PD-1/PD-L1 blockade immunotherapy in recurrent/metastatic high-grade neuroendocrine carcinoma of the cervix: A retrospective study
by: Haifeng Qiu, et al.
Published: (2024-09-01) -
Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients
by: Karczmarczyk A, et al.
Published: (2022-03-01) -
Programmed cell death protein 1 and programmed death ligand 1 expression in neuroendocrine carcinomas of the urinary bladder
by: Arbil Acikalin, et al.
Published: (2021-02-01) -
Regulation of Neuroinflammation through Programmed Death-1/Programmed Death Ligand Signaling in Neurological Disorders
by: Shangfeng eZhao, et al.
Published: (2014-09-01) -
Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
by: Otgontuya Ganbaatar, et al.
Published: (2021-12-01)